Anavex Life Sciences Corp.
(NASDAQ : AVXL)

( )
AVXL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.55%73.740.9%$598.99m
CELGCelgene Corporation
-0.84%129.191.1%$425.21m
AMGNAmgen Inc.
-0.63%169.001.1%$397.19m
BIIBBiogen Inc.
-1.42%282.641.2%$346.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.31%477.152.7%$319.17m
VRTXVertex Pharmaceuticals Incorporated
-1.43%153.251.9%$227.49m
ALXNAlexion Pharmaceuticals, Inc.
-1.83%135.671.9%$211.59m
ILMNIllumina, Inc.
-0.59%193.623.5%$208.34m
KITEKite Pharma, Inc.
1.63%138.1716.1%$135.10m
INCYIncyte Corporation
-0.17%123.652.6%$130.04m
CLVSClovis Oncology, Inc.
-0.68%71.6118.0%$125.25m
TSROTESARO, Inc.
-0.18%120.4014.7%$124.85m
AAgilent Technologies, Inc.
-0.30%62.771.5%$122.45m
BMRNBioMarin Pharmaceutical Inc.
-0.07%81.404.4%$105.16m
SRPTSarepta Therapeutics, Inc.
-2.38%36.0719.8%$88.80m

Company Profile

Anavex Life Sciences Corp. engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. It's lead compound, ANAVEXTM 2-73, is being developed to treat Alzheimer's disease, Parkinson's disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.